1. Scrip
  2. >>Scrip Asks

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

Digital And Data Revolution Drives Change

 
• By Eleanor Malone

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.

Scrip Asks, Part 5
• Source: Shutterstock

The executives we surveyed on the clinical trial landscape identified several sweeping trends that are expected to drive change over the coming year. As in so many spheres, data, digital technology and artificial intelligence (AI) are at the heart of much of this change.

“In 2024, the core trend in the clinical trial landscape will be leading biopharma and service provider organizations sifting through and synthesizing a convergence of factors as they attempt to construct effective study designs,” said Moisha Platto, chief operating officer of clinical trial patient services provider Scout Clinical. “Such factors include integration of technologies, leveraging artificial intelligence, and lessons learned from the pandemic

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip Asks

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

 
• By Eleanor Malone

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 
• By Eleanor Malone

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 4: Artificial Intelligence and Data Science

 
• By Eleanor Malone

More than 50 executives across industry share their expectations for the impact of AI on the biopharma industry over the coming year. While target identification and drug discovery featured highly, the opportunities to engage with patients and healthcare providers more effectively and the need for suitable regulatory frameworks were also flagged up.

Scrip Asks… What Does 2025 Hold For Biopharma? Part 3: Impacts Of Political Change In US And Beyond

 
• By Eleanor Malone

What do industry leaders anticipate as the US installs president Trump once again? Beyond the biopharma sector's biggest market, geopolitical instability has increased elsewhere: how might this affect markets and companies?

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.